$39.97
-0.03-0.08%
Last update: Oct 30, 7:58 PM
Novo Nordisk AS
NVONYSE
Novo Nordisk (NVO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Novo Nordisk (NVO) last issued guidance on May 6, 2026 for fiscal year 2026. The company guided revenue in the range of $42.39B - $46.24B for the period.
Compared to prior guidance, Novo Nordisk raised its revenue forecast from a prior range of $40.46B - $44.32B.
Novo Nordisk has issued 15 guidance updates between November 2, 2022 and May 6, 2026. During this period, the company raised its outlook 11 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.81 | $0.87 | $0.89 | $0.77 |
| Actual | $0.96 | $1.04 | $1.00 | $1.03 |
| Surprise | +18.6% | +19.3% | +12.4% | +33.4% |
| Revenue | ||||
| Estimate | $11.35B | $11.13B | $12.08B | $11.88B |
| Actual | $12.21B | $15.17B | $12.34B | $11.74B |
| Surprise | +7.57% | +36.3% | +2.11% | -1.14% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.81 | $0.70 | $0.91 | $0.92 |
| Revenue | ||||
| Consensus | $11.39B | $11.96B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $0.96 | $0.81 | 18.6 % |
| Q1 | May 6, 2026 | $1.04 | $0.87 | 19.3 % |
| Q4 | Feb 4, 2026 | $1.00 | $0.89 | 12.4 % |
| Q3 | Nov 5, 2025 | $1.03 | $0.77 | 33.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $12.21B | $11.35B | 7.57 % |
| Q1 | May 6, 2026 | $15.17B | $11.13B | 36.3 % |
| Q4 | Feb 4, 2026 | $12.34B | $12.08B | 2.11 % |
| Q3 | Nov 5, 2025 | $11.75B | $11.88B | -1.14 % |
